Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Drug Discovery"
DOI: 10.1080/17460441.2019.1546691
Abstract: ABSTRACT Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major depressive disorder (MDD) in adults. It is formulated into tablets and has a dose range of 5–20 mg. The recommended starting… read more here.
Keywords: vortioxetine; depressive disorder; treatment major; major depressive ... See more keywords
Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine
Sign Up to like & getrecommendations! Published in 2022 at "Hormone Molecular Biology and Clinical Investigation"
DOI: 10.1515/hmbci-2021-0099
Abstract: Abstract Esketamine, which is an S-enantiomer of ketamine, is better than conventional antidepressants and even better than R-ketamine. This article discusses the mechanism of action of Esketamine, how different it is from other antidepressants, its… read more here.
Keywords: quick acting; acting novel; novel antidepressant; antidepressant without ... See more keywords
Therapeutic Effect of Novel Antidepressant Drugs Acting at Specific Receptors of Neurotransmitters and Neuropeptides.
Sign Up to like & getrecommendations! Published in 2019 at "Current pharmaceutical design"
DOI: 10.2174/1381612825666190410165243
Abstract: BACKGROUND Major depression is a frequent psychiatric disease. One- third of the depressive patients remain treatment-resistant; thus, it is urgent to find novel antidepressant drugs. OBJECTIVE In major depression, in several brain areas the neural… read more here.
Keywords: receptor antagonist; antidepressant drugs; neurotransmitters neuropeptides; effect ... See more keywords